To further evaluate the prognostic value of our APM model, we compared its performance to two widely used frameworks to evaluate immunogenicity and prognosis to ICB: cytolytic score (CYT)24 as the log average expression of GZMA and PRF1, and Tumor Immune Dysfunction and Exclusion (TIDE) score25. The gene discussed is GZMA; the disease is neoplasm.